Parkinson Disease
Conditions
Keywords
Speech, Emotion, Movement, Cognition, Biomarker, Automated speech analysis
Brief summary
With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.
Detailed description
Parkinson's disease (PD) affects mobility (motor function), thought processes (cognition) and mood (emotion). The language is one of the most complex programs in humans. It contains information about mobility, thinking and mood at the same time. These three levels of agility, thinking and mood are subject to spontaneous fluctuations and can be influenced by external stimuli such as pictures that induce emotions. In addition, these three levels are influenced on the one hand by Parkinson's disease itself, and on the other hand by its treatment with medication or with deep brain stimulation (DBS). For this reason, the investigators would like to investigate language in Parkinson's disease patients in a very detailed computerized way for motor, cognitive and emotional elements for better management of therapies. With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect fluctuations in motor, mood, and thinking in Parkinson's disease patients. Even in healthy subjects, speech changes in a situational manner, due to which the investigators will also include healthy subjects as a control group.
Interventions
OTHERDopaminergic OFF drug state
Experiment will be performed without dopaminergic medication
OTHERDBS OFF state
Turning off the stimulation during experiment
OTHERDopaminergic ON drug state
Experiment will be performed with dopaminergic medication
OTHERDBS ON state
Experiment will be performed with stimulation (ON condition)
Sponsors
Insel Gruppe AG, University Hospital Bern
Czech Technical University in Prague
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Patients with Parkinson's Disease Inclusion Criteria: * Written informed consent * Idiopathic PD according to the Movement Disorders Society Criteria; * Age of participants \> 30 and ≤ 75 years; * Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus; * Fluent in German or French
Exclusion criteria
* Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia); * Clinical diagnosis of aphasia; * Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.). * Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points); * Depression with acute suicidal ideation Healthy Controls Inclusion Criteria: * Written informed consent * Adults from 50-70 years old; * Fluent in German or French
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients | Visit 2 (< 3 months) | A speech analyser software will allow extraction of basic motor acoustic speech features. The extracted variables that better index the dopaminergic medication or stimulation motor effect assessed with Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III - motor score \[0-132 pts.\] will be used as primary outcomes in this part. Higher scores in MDS-UPDRS part III means more severe motor symptoms. |
| Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients | Visit 2 (< 3 months) | A speech analyser software will allow extraction of basic acoustic speech features. For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality. The extracted variables that better index the dopaminergic medication or stimulation emotional effect assessed with Neuropsychiatric fluctuations scale (NFS) \[0-60 pts.\] will be used as primary outcomes in this part. Higher scores in NFS means more severe neuropsychiatric fluctuations. |
| Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients | Visit 2 (< 3 months) | A speech analyser software will allow extraction of basic acoustic speech features. For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality. The extracted variables that better index the dopaminergic medication or stimulation cognitive effect assessed with verbal fluency task will be used as primary outcomes in this part. Higher scores in Fluency task means better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dyskinesia severity | At visit 1 (baseline) and visit 2 (< 3 months) | Score on Marconi dyskinesia rating scale \[0-28 pts.\]. Higher scores in Marconi dyskinesia rating scale means more severe dyskinesia. |
| Momentary mood state | At visit 1 (baseline) and visit 2 (< 3 months) | Score on Visual Analogue Mood Scale (VAMS) \[0-100 pts.\]. Higher scores in VAMS means better mood. |
| Momentary anxiety state | At visit 1 (baseline) and visit 2 (< 3 months) | Score on Visual Analogue Anxiety Scale (VAAS) \[0-100 pts.\]. Higher scores in VAAS means more anxiety. |
| Bradyphrenia assessment | At visit 1 (baseline) and visit 2 (< 3 months) | Score on Bradyphrenia scale \[0-72 pts.\]. Higher scores in Bradyphrenia scale means more severe bradyphrenia. |
Countries
Czechia, Switzerland
Contacts
CONTACTPaul Krack, Prof.
CONTACTMario Sousa, MD
PRINCIPAL_INVESTIGATORPaul Krack, Prof.
Insel Gruppe AG, University Hospital Bern
Outcome results
None listed